Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q4 2025
Rhythm Pharmaceuticals (RYTM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Rhythm Pharmaceuticals (RYTM) reported revenue of $57.3M for the fourth quarter 2025 (Q4 2025), +37% from a year earlier and +12% from the quarter before. Operating margin was -82.2%, net loss $47.5M (83.0% of revenue).
Rhythm Pharmaceuticals, Q4 2025: revenue $57.3M (+37% year over year), operating margin -82.2%, net loss $47.5M, operating cash flow −$25.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $57.3M | +12% | +37% |
| Operating profit | −$47.1M | — | — |
| Net earnings | −$47.5M | — | — |
| Operating cash flow | −$25.4M | — | — |
What changed
Revenue was $57.3M in Q4 2025, up 37% year over year and up 12% from the previous quarter.
Operating costs exceeded revenue by $47.1M, an operating margin of -82.2%. Total costs grew 26% against revenue growth of 37%. The fastest-growing cost line was SG&A (+51%). The quarter ended with a net loss of $47.5M, narrower than the previous quarter's $52.9M loss.
Operating cash flow was −$25.4M. Non-cash charges added back $19.3M of share-based compensation. Working capital and other items added $2.9M.
Questions
What was Rhythm Pharmaceuticals' revenue in the fourth quarter 2025?
Rhythm Pharmaceuticals (RYTM) reported revenue of $57.3M for the fourth quarter 2025 (Q4 2025), +37% from a year earlier and +12% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $47.1M (-82.2% of revenue) and net loss $47.5M.